This application seeks 2 years of funding to complete COMBINE and its ancillary cost-effectiveness and genetic predictors of treatment response studies. The COMBINE study was initiated in 1997 to answer questions about the benefits of combining behavioral and pharmacological interventions. Two medications, naltrexone and acamprosate, have shown promise in reducing relapse to heavy drinking and improving abstinence in a number of U.S. and European clinical trials. The two behavioral treatments, Medical Management (MM) and Combined Behavioral Intervention (CBI), have potential to be valuable adjuncts to pharmacotherapy. MM appears to be cost-effective and suitable for delivery in primary care or managed care settings by non-specialists. The primary hypothesis is that combining naltrexone and acamprosate with a moderate intensity behavioral treatment (CBI) will yield better outcomes than less intensive approaches (e.g., placebo and MM; acamprosate or naltrexone and MM). A total of 1375 subjects from 11 clinical sites comprise the targeted sample. Individuals meeting study criteria have been randomly assigned to one of 9 pharmacological and behavioral treatment combinations to form a complete 2X2X2 factorial design. A ninth cell was later included to test the efficacy of CBI without """"""""pills."""""""" Much has been accomplished thus far. Over 70% of the intended sample has been randomized, reflecting gender, ethnic, geographic, and clinical diversity. Drinking assessment interviews have been completed for 84% of clients at 16-week follow-up. Two major pilot studies were successfully completed and the findings have been disseminated at conferences and in publications. The requested 2-year extension will allow for the recruitment, treatment, and follow-up of the remaining participants, and allow sufficient time for data analysis and manuscript preparation. Results from COMBINE are expected to have a Major Impact on the alcohol treatment system. A common protocol across each study site is submitted, reflecting the cooperative process that has guided the study. However, each study site has provided site-specific information on the budget, budget justifications, listing of key personnel, Consultant/consortium agreements, and human subjects sections of their respective proposals.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10AA011756-07
Application #
6682615
Study Section
Special Emphasis Panel (ZAA1-BB (10))
Program Officer
Litten, Raye Z
Project Start
1997-09-30
Project End
2005-08-31
Budget Start
2003-09-15
Budget End
2004-08-31
Support Year
7
Fiscal Year
2003
Total Cost
$476,226
Indirect Cost
Name
Mc Lean Hospital (Belmont, MA)
Department
Type
DUNS #
046514535
City
Belmont
State
MA
Country
United States
Zip Code
02478
McHugh, R Kathryn; Kaufman, Julia S; Frost, Katherine H et al. (2013) Positive affect and stress reactivity in alcohol-dependent outpatients. J Stud Alcohol Drugs 74:152-7
Doyle, Suzanne R; Donovan, Dennis M; Simpson, Tracy L (2011) Validation of a nine-dimensional measure of drinking motives for use in clinical applications: the desired effects of drinking scale. Addict Behav 36:1052-60
Greenfield, Shelly F; Pettinati, Helen M; O'Malley, Stephanie et al. (2010) Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res 34:1803-12
Oroszi, Gabor; Anton, Raymond F; O'Malley, Stephanie et al. (2009) OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res 33:383-93
Doyle, Suzanne R; Donovan, Dennis M (2009) A validation study of the alcohol dependence scale. J Stud Alcohol Drugs 70:689-99
Ray, Lara A; Oslin, David W (2009) Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study. Drug Alcohol Depend 105:256-8
DiClemente, Carlo C; Doyle, Suzanne R; Donovan, Dennis (2009) Predicting treatment seekers' readiness to change their drinking behavior in the COMBINE Study. Alcohol Clin Exp Res 33:879-92
Anton, Raymond F; Oroszi, Gabor; O'Malley, Stephanie et al. (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65:135-44
Ernst, Denise B; Pettinati, Helen M; Weiss, Roger D et al. (2008) An intervention for treating alcohol dependence: relating elements of Medical Management to patient outcomes with implications for primary care. Ann Fam Med 6:435-40
Weiss, Roger D; O'malley, Stephanie S; Hosking, James D et al. (2008) Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study. J Stud Alcohol Drugs 69:878-84

Showing the most recent 10 out of 20 publications